First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

詳細情報 詳細情報について

• CRID

  1360016870546888576

• DOI

  10.1016/j.jtho.2021.09.010

• ISSN

  15560864

• Web Site

  https://api.elsevier.com/content/article/PII:S155608642103207X?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S155608642103207X?httpAccept=text/plain

• データソース種別

  • Crossref